89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.
Ritonavir-boosted nirmatrelvir
Abacavir/lamivudine
Baloxavir marboxil
Emtricitabine/tenofovir
HIV post-exposure prophylaxis
Ribavirin
Lopinavir
Raltegravir